Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission
Adia Nutrition (OTCQB: ADIA) has engaged an independent accounting firm and securities counsel to prepare and file a Form 10 with the U.S. SEC, marking a move from OTC reporting to full SEC reporting.
The company expects to submit the Form 10 by end of November 2025, notes an SEC review/recognition period of 60 days, and anticipates the filing becoming effective by late January 2026. Full reporting will require audited financials, regular disclosures, and enhanced governance and is presented as a step toward meeting Nasdaq listing requirements and attracting institutional and accredited investors.
Adia Nutrition (OTCQB: ADIA) ha incaricato uno studio contabile indipendente e un avvocato specializzato in titoli per preparare e presentare un Form 10 presso la SEC statunitense, segnando un passaggio dalla rendicontazione OTC a quella completa SEC.
L'azienda prevede di presentare il Form 10 entro la fine di novembre 2025, segnala un periodo di verifica/riconoscimento da parte della SEC di 60 giorni e si aspetta che la presentazione entri in vigore entro la fine di gennaio 2026. Una rendicontazione completa richiederà bilanci certificati, comunicazioni regolari e una governance potenziata, ed è presentata come un passo verso il rispetto dei requisiti di quotazione Nasdaq e l'attrazione di investitori istituzionali e accreditati.
Adia Nutrition (OTCQB: ADIA) ha contratado a una firma de contabilidad independiente y a asesoría de valores para preparar y presentar un Form 10 ante la SEC de EE. UU., marcando un paso desde la información OTC hacia la información completa de la SEC.
La empresa espera presentar el Form 10 para finales de noviembre de 2025, señala un periodo de revisión/reconocimiento de la SEC de 60 días y prevé que la presentación entre en vigor para finales de enero de 2026. La información completa requerirá estados financieros auditados, divulgaciones regulares y una gobernanza mejorada, y se presenta como un paso para cumplir con los requisitos de cotización de Nasdaq y atraer inversores institucionales y acreditados.
Adia Nutrition (OTCQB: ADIA)가 독립 회계법인 및 증권 고문을 고용하여 미국 SEC에 Form 10을 작성·제출하여 OTC 보고에서 SEC 전체 보고로의 전환을 표시합니다.
회사는 2025년 11월 말까지 Form 10을 제출할 예정이며, SEC의 검토/인정 기간은 60일로 보고하고 있으며, 제출이 2026년 1월 말까지 발효될 것으로 기대합니다. 전체 보고는 감사받은 재무제표, 정기 공시, 향상된 거버넌스를 필요로 하며, Nasdaq 상장 요건 충족 및 기관 및 인증받은 투자자 유치를 위한 단계로 제시됩니다.
Adia Nutrition (OTCQB: ADIA) a fait appel à un cabinet comptable indépendant et à des avocats spécialisés en valeurs mobilières pour préparer et déposer un Form 10 auprès de la SEC américaine, marquant une transition du reporting OTC au reporting complet de la SEC.
L'entreprise prévoit de soumettre le Form 10 d'ici fin novembre 2025, note une période d'examen/ reconnaissance par la SEC de 60 jours, et anticipe que le dépôt deviendra effectif d'ici fin janvier 2026. Le reporting complet nécessitera des états financiers audités, des divulgations régulières et une gouvernance renforcée, et il est présenté comme une étape vers le respect des exigences de cotation Nasdaq et l'attraction d'investisseurs institutionnels et accrédités.
Adia Nutrition (OTCQB: ADIA) hat eine unabhängige Wirtschaftsprüfungsgesellschaft und einen Wertpapierrechtsexperten beauftragt, um eine Form 10 bei der US-Börsenaufsicht SEC vorzubereiten und einzureichen, was den Übergang von OTC-Berichterstattung zu vollem SEC-Reporting markiert.
Das Unternehmen erwartet, das Form 10 bis Ende November 2025 einzureichen, vermerkt eine Prüfungs-/Anerkennungsfrist der SEC von 60 Tagen und geht davon aus, dass die Einreichung bis Ende Januar 2026 wirksam wird. Das volle Reporting wird geprüfte Finanzberichte, regelmäßige Offenlegungen und eine verbesserte Unternehmensführung erfordern und wird als Schritt gesehen, um die Anforderungen der Nasdaq-Notierung zu erfüllen und institutionelle sowie akkreditierte Investoren anzuziehen.
Adia Nutrition (OTCQB: ADIA) وظّفت شركة محاسبة مستقلة ومستشارين في الأوراق المالية لإعداد وتقديم Form 10 لدى هيئة الأوراق المالية الأمريكية (SEC)، وهو خطوة من الإبلاغ OTC إلى الإبلاغ الكامل لدى SEC.
تتوقع الشركة تقديم Form 10 بحلول نهاية نوفمبر 2025، مع فترة مراجعة/اعتراف من SEC تستغرق 60 يوماً، وتتوقع أن يصبح filing ساري المفعول بحلول أواخر يناير 2026. الإبلاغ الكامل سيتطلب بيانات مالية مدققة وإفصاحات منتظمة وحوكمية محسّنة، ويُقدّم كخطوة نحو تلبية متطلبات الإدراج في Nasdaq وجذب المستثمرين المؤسسيين والمعتمدين.
Adia Nutrition (OTCQB: ADIA) 已聘请一家独立会计事务所和证券顾问，准备并向美国证监会SEC提交一份 Form 10，标志着从OTC披露向SEC全面披露的转变。
公司预计在2025年11月底提交Form 10，SEC的审查/认可期为60天，并预计该提交在2026年1月底前生效。全面披露将需要经审计的财务报表、定期披露和治理强化，并被视为实现< b>Nasdaq上市要求及吸引机构和有资格投资者的一步。
- Planned Form 10 submission by end of November 2025
- SEC review/recognition period specified as 60 days
- Anticipated Form 10 effectiveness by late January 2026
- Positions company to pursue Nasdaq listing
- Full SEC reporting enables access to institutional investors
- Full SEC reporting requires comprehensive audited financials
- Transition entails enhanced governance and disclosure obligations
- Company must complete audits and documentation before submission
Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing marks a significant step beyond OTC reporting and positions Adia as a fully reporting public company under the Securities Exchange Act of 1934, a critical move that enhances transparency, credibility, and access to the broader capital markets. Unlike OTC reporting, which provides limited disclosure, full SEC reporting requires comprehensive audited financials, regular operational updates, and robust corporate governance, all of which unlock new opportunities for growth and investment.
Adia expects to submit the Form 10 by the end of November 2025, with the SEC review and recognition period set at 60 days. Based on this timeline, the filing is anticipated to become fully effective by late January 2026. This advancement is also a key step toward meeting Nasdaq listing requirements, bringing Adia closer to joining one of the world's most prestigious stock exchanges and attracting a new class of institutional and accredited investors.
"Filing the Form 10 is a transformative moment for Adia Nutrition," said Larry Powalisz, CEO of Adia Nutrition Inc. "Transitioning from OTC reporting to full SEC compliance elevates our visibility and credibility, opens doors to sophisticated investors, and sets the stage for strategic growth opportunities as we continue expanding our leadership in regenerative medicine, advanced biologics, and clinical services nationwide."
With full SEC reporting status, Adia expects to attract institutional investors, mutual funds, and accredited investors who typically only invest in fully reporting companies. The increased transparency and regulatory compliance will also enable strategic partnerships and broader market recognition, fueling the next stage of Adia's rapid expansion. The Company's accounting and legal teams are finalizing documentation and audits to ensure a smooth submission, and shareholders can expect regular updates as the filing and SEC recognition process progresses.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270232
FAQ
When will Adia Nutrition (ADIA) file its Form 10 with the SEC?
How long is the SEC review period for Adia Nutrition's Form 10 (ADIA)?
When could Adia Nutrition (ADIA) become a fully reporting SEC company?
Does filing Form 10 help Adia Nutrition (ADIA) list on Nasdaq?
What does full SEC reporting require for Adia Nutrition (ADIA)?
Will Adia Nutrition (ADIA) attract institutional investors after Form 10?
How can investors or partners contact Adia Nutrition about ADIA updates or licensing?
